These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 32402096)

  • 21. Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring EGFR mutations.
    Ichihara E; Hotta K; Takigawa N; Kudo K; Kato Y; Honda Y; Hayakawa H; Minami D; Sato A; Tabata M; Tanimoto M; Kiura K
    Lung Cancer; 2013 Sep; 81(3):435-439. PubMed ID: 23809059
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902.
    Sugawara S; Oizumi S; Minato K; Harada T; Inoue A; Fujita Y; Maemondo M; Yoshizawa H; Ito K; Gemma A; Nishitsuji M; Harada M; Isobe H; Kinoshita I; Morita S; Kobayashi K; Hagiwara K; Kurihara M; Nukiwa T
    Ann Oncol; 2015 May; 26(5):888-894. PubMed ID: 25669832
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of genetic alterations associated with primary resistance to EGFR-TKIs in advanced non-small-cell lung cancer patients with EGFR sensitive mutations.
    Wang F; Diao XY; Zhang X; Shao Q; Feng YF; An X; Wang HY
    Cancer Commun (Lond); 2019 Mar; 39(1):7. PubMed ID: 30823937
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutations.
    Uchibori K; Satouchi M; Sueoka-Aragane N; Urata Y; Sato A; Imamura F; Inoue T; Tachihara M; Kobayashi K; Katakami N; Kokan C; Hirashima T; Iwanaga K; Mori M; Aoe K; Morita S; Negoro S
    Lung Cancer; 2018 Oct; 124():65-70. PubMed ID: 30268482
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations.
    Lin YT; Chen JS; Liao WY; Ho CC; Hsu CL; Yang CY; Chen KY; Lee JH; Lin ZZ; Shih JY; Yang JC; Yu CJ
    Int J Cancer; 2019 Jun; 144(11):2887-2896. PubMed ID: 30485437
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3.
    Shou J; You L; Yao J; Xie J; Jing J; Jing Z; Jiang L; Sui X; Pan H; Han W
    Cancer Lett; 2016 Aug; 379(1):124-33. PubMed ID: 27264264
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overall survival of super-elderly (85 years or older) advanced non-small cell lung cancer patients with active epidermal growth factor receptor mutations receiving first-line gefitinib therapy: a single-institute retrospective study.
    Kashiwabara K; Fujii S; Tsumura S; Sakamoto K
    J Cancer Res Clin Oncol; 2021 Jan; 147(1):287-293. PubMed ID: 32761377
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of Exon 19 Deletion Subtypes in EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer Treated With First-Line Tyrosine Kinase Inhibitors.
    Rossi S; Toschi L; Finocchiaro G; Di Noia V; Bonomi M; Cerchiaro E; Ceresoli GL; Beretta GD; D'Argento E; Santoro A
    Clin Lung Cancer; 2019 Mar; 20(2):82-87. PubMed ID: 30473385
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Liver metastasis predicts poorer prognosis in stage IV lung adenocarcinoma patients receiving first-line gefitinib.
    Wu KL; Tsai MJ; Yang CJ; Chang WA; Hung JY; Yen CJ; Shen CH; Kuo TY; Lee JY; Chou SH; Liu TC; Chong IW; Huang MS
    Lung Cancer; 2015 May; 88(2):187-94. PubMed ID: 25747806
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasma exosomal DOK3 reflects immunological states in lung tumor and predicts prognosis of gefitinib treatment.
    Ochiai R; Hayashi K; Yamamoto H; Fujii R; Saichi N; Shinchi H; Ishida T; Honda T; Shimizu T; Matsutani N; Seki N; Kawamura M; Ueda K
    Cancer Sci; 2022 Nov; 113(11):3960-3971. PubMed ID: 36028467
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study.
    Lee JK; Shin JY; Kim S; Lee S; Park C; Kim JY; Koh Y; Keam B; Min HS; Kim TM; Jeon YK; Kim DW; Chung DH; Heo DS; Lee SH; Kim JI
    Ann Oncol; 2013 Aug; 24(8):2080-7. PubMed ID: 23559152
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer.
    Zhang XT; Li LY; Mu XL; Cui QC; Chang XY; Song W; Wang SL; Wang MZ; Zhong W; Zhang L
    Ann Oncol; 2005 Aug; 16(8):1334-42. PubMed ID: 15956035
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical Impact of Gastric Acid-Suppressing Medication Use on the Efficacy of Erlotinib and Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations.
    Zenke Y; Yoh K; Matsumoto S; Umemura S; Niho S; Ohmatsu H; Goto K; Ohe Y
    Clin Lung Cancer; 2016 Sep; 17(5):412-418. PubMed ID: 26944770
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study.
    Pilotto S; Rossi A; Vavalà T; Follador A; Tiseo M; Galetta D; Morabito A; Di Maio M; Martelli O; Caffo O; Piovano PL; Cortinovis D; Zilembo N; Casartelli C; Banna GL; Ardizzoia A; Barzelloni ML; Bearz A; Genestreti G; Mucciarini C; Filipazzi V; Menis J; Rizzo E; Barbieri F; Rijavec E; Cecere F; Spitaleri G; Bria E; Novello S
    Clin Lung Cancer; 2018 Jan; 19(1):93-104. PubMed ID: 28645631
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination of Metformin and Gefitinib as First-Line Therapy for Nondiabetic Advanced NSCLC Patients with EGFR Mutations: A Randomized, Double-Blind Phase II Trial.
    Li L; Jiang L; Wang Y; Zhao Y; Zhang XJ; Wu G; Zhou X; Sun J; Bai J; Ren B; Tian K; Xu Z; Xiao HL; Zhou Q; Han R; Chen H; Wang H; Yang Z; Gao C; Cai S; He Y
    Clin Cancer Res; 2019 Dec; 25(23):6967-6975. PubMed ID: 31413010
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy.
    Yang CJ; Hung JY; Tsai MJ; Wu KL; Liu TC; Chou SH; Lee JY; Hsu JS; Huang MS; Chong IW
    BMC Pharmacol Toxicol; 2017 May; 18(1):21. PubMed ID: 28486985
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Efficacy of erlotinib after the failure of gefitinib in patients with metastasis of non-small cell lung cancer with unknown EGFR mutation status].
    Wang Y; Li JL; Wang ZP; Hao XZ; Wang B; Zhang XR; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):780-4. PubMed ID: 23291074
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rational application of gefitinib in NSCLC patients with sensitive EGFR mutations based on pharmacokinetics and metabolomics.
    Feng W; Chen X; Guan SX; Ruan HL; Huang Y; Zhang HZ; Yang YP; Fang WF; Zhao HY; Zhuang W; Xin S; Chen YH; Wang F; Gao Y; Huang M; Wang XD; Zhang L
    Acta Pharmacol Sin; 2022 Jul; 43(7):1857-1864. PubMed ID: 34737420
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer.
    Liu K; Jiang G; Zhang A; Li Z; Jia J
    BMC Cancer; 2020 Jan; 20(1):76. PubMed ID: 32000711
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of gefitinib efficacy according to body mass index, body surface area, and body weight in patients with EGFR-mutated advanced non-small cell lung cancer.
    Imai H; Kuwako T; Kaira K; Masuda T; Miura Y; Seki K; Sakurai R; Utsugi M; Shimizu K; Sunaga N; Tomizawa Y; Ishihara S; Ishizuka T; Mogi A; Hisada T; Minato K; Takise A; Saito R; Yamada M
    Cancer Chemother Pharmacol; 2017 Mar; 79(3):497-505. PubMed ID: 28168310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.